For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
Myriad Genetics, Inc (NASDAQ: MYGN) closed the day trading at $6.11 down -1.45% from the previous closing price of $6.2. In other words, the price has decreased by -$1.45 from its previous closing price. On the day, 0.98 million shares were traded. MYGN stock price reached its highest trading level at $6.17 during the session, while it also had its lowest trading level at $5.9.
Ratios:
For a better understanding of MYGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.12 and its Current Ratio is at 2.33. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.55.
Wells Fargo Downgraded its Overweight to Equal Weight on May 07, 2025, while the target price for the stock was maintained at $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 569535872 and an Enterprise Value of 636435840. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.69 while its Price-to-Book (P/B) ratio in mrq is 1.53. Its current Enterprise Value per Revenue stands at 0.771 whereas that against EBITDA is -24.291.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.90, which has changed by -0.50479233 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $15.47, while it has fallen to a 52-week low of $3.76. The 50-Day Moving Average of the stock is -10.14%, while the 200-Day Moving Average is calculated to be -4.28%.
Shares Statistics:
Over the past 3-months, MYGN traded about 1.04M shares per day on average, while over the past 10 days, MYGN traded about 830380 shares per day. A total of 93.10M shares are outstanding, with a floating share count of 88.76M. Insiders hold about 4.78% of the company’s shares, while institutions hold 97.56% stake in the company. Shares short for MYGN as of 1767139200 were 9635344 with a Short Ratio of 9.24, compared to 1764288000 on 8565850. Therefore, it implies a Short% of Shares Outstanding of 9635344 and a Short% of Float of 14.52.
Earnings Estimates
Current recommendations for the stock of the company come from 11.0 analysts. The consensus estimate for the next quarter is $0.0, with high estimates of $0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.02 and -$0.03 for the fiscal current year, implying an average EPS of $0.0. EPS for the following year is $0.07, with 11.0 analysts recommending between $0.19 and -$0.03.
Revenue Estimates
10 analysts predict $207.15M in revenue. The current quarter. It ranges from a high estimate of $209.79M to a low estimate of $204.68M. As of. The current estimate, Myriad Genetics, Inc’s year-ago sales were $210.6MFor the next quarter, 10 analysts are estimating revenue of $212.46M. There is a high estimate of $218.38M for the next quarter, whereas the lowest estimate is $207.1M.
A total of 5 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $823M, while the lowest revenue estimate was $822M, resulting in an average revenue estimate of $822.56M. In the same quarter a year ago, actual revenue was $837.6MBased on 8 analysts’ estimates, the company’s revenue will be $870.1M in the next fiscal year. The high estimate is $882M and the low estimate is $862.26M.
